Medicine and Dentistry
Hepatitis B Virus
83%
Patient
80%
Combination Therapy
73%
Therapeutic Procedure
56%
Cells
54%
Neoplasm
54%
Chronic Hepatitis B
50%
Statin
46%
Antibody
46%
Hepatitis B Core Antigen
46%
Hepatitis C Virus
46%
Hepatitis B Antigen
46%
CTLA-4
38%
Nucleotide
38%
Antivirus Agent
38%
Development
34%
Nonalcoholic Fatty Liver
32%
Regulatory T Cell
31%
Immunosuppressive Treatment
31%
Tenofovir Disoproxil
29%
Association
29%
Hepatitis B(e) Antigen
27%
Peginterferon
27%
Viral Clearance
25%
Liver Cancer
25%
Liver
22%
Plasmacytoid Dendritic Cell
20%
Liver Tumor
20%
Ex Vivo
20%
T Cell
20%
Virus DNA
20%
Hepatocellular Carcinoma
18%
Ligand
18%
Inpatient
17%
Ligation
15%
Drug
15%
Chemotherapeutic Agent
15%
Fibrosis
14%
Serum
13%
Relapse
13%
Hepatitis B
13%
Liver Metastasis
12%
Colorectal Cancer
12%
T-Cell Response
12%
Alanine Aminotransferase
12%
Infection
12%
Chronic Hepatitis C
10%
Diagnosis
10%
Hepatitis C
10%
Retreatment
9%
Immunology and Microbiology
Hepatitis B
100%
Liver
99%
Regulatory T Cell
98%
Hepatitis B Virus
81%
Hepatitis C Virus
56%
Hepatitis B Virus
55%
HBcAg
46%
Development
46%
Viral Disease
43%
Monospecific Antibody
41%
Tumor Necrosis Factor Receptor
38%
Glucocorticoid
38%
CTLA-4
38%
Hepatitis C
35%
Virus Core
31%
Protein Targeting
31%
Nomenclature
31%
Pegylated Interferon
27%
Hepatitis B(e) Antigen
27%
Immunosuppression
25%
HBsAg
25%
Incidence
23%
Plasmacytoid Dendritic Cell
20%
Inflammation
20%
CD4
18%
Cells
18%
Gene
17%
Molecule
15%
Virus Antigen
15%
Dendritic Cell Function
15%
Innate Immune System
15%
Adaptive Immune System
15%
Virus
15%
Antiviral Immune Response
15%
Human
12%
Time
11%
Sex
11%
Antigen
9%
Genotype
8%
Association
8%
Clearance
8%
Cell Function
7%
Low Drug Dose
7%
Immunity
7%
Blocking Antibody
7%
Cytokine Production
7%
Immunity
5%
Solid
5%
Immunoregulation
5%
Cell Population
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
81%
Chronic Hepatitis C
58%
Normal Human
46%
Toll Like Receptor 7
46%
Chronic Hepatitis B
36%
Hepatitis B Surface Antigen
32%
Tenofovir Disoproxil
29%
Agonist
27%
Hepatitis B Virus
23%
Antiviral Activity
23%
Proteinase Inhibitor
23%
Pharmacokinetics
23%
Interferon
22%
Hepatitis C
21%
Deterioration
20%
RNA
20%
Alpha Interferon
18%
Virus DNA
15%
Relapse
13%
Human
12%
Hepatitis C Virus
12%
Drug Administration
11%
Clinical Trial Design
11%
Tolerability
11%
Blindness
11%
Clinical Trial
11%
Study Design
11%
Controlled Clinical Trial
11%
Protein
9%
Subcutaneous Injection
7%
Alanine Aminotransferase
7%
Fever
7%
Antivirus Agent
7%
Antisense Oligonucleotide
7%
Injection Site Reaction
7%
Adverse Event
7%
Nucleoside
7%
Virus Messenger RNA
7%
Fatigue
7%
Infection
7%
Viral Protein
7%